Die Europäische Kommission beruft Ingmar Hoerr, Mitgründer und Aufsichtsratsvorsitzender von CureVac, zum Beirat des Europäischen Innovationsrats
July 01, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland und BOSTON, July 01, 2019 (GLOBE NEWSWIRE) -- Die CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gratuliert CureVacs Mitgründer und...
CureVac Welcomes Two Members to its Supervisory Board
June 24, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, June 24, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that Timothy Wright,...
CureVac werden drei Patente zur intratumoralen Applikation von RNA erteilt
June 13, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland und BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gab die...
CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA
June 13, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that it received a...
CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
May 20, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, May 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a...
CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
April 16, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has been...
CureVac to Participate in Upcoming Investor Conferences
April 09, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced its...
CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
March 21, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it will present...
CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
February 27, 2019 07:30 ET
|
CureVac AG
OSLO, Norway, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines,...
CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference
February 19, 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...